WO2022066714A3 - Delivery of sfrp-3 or foxm1 inhibitor to protect from and treat mitral regurgitation and heart failure - Google Patents

Delivery of sfrp-3 or foxm1 inhibitor to protect from and treat mitral regurgitation and heart failure Download PDF

Info

Publication number
WO2022066714A3
WO2022066714A3 PCT/US2021/051478 US2021051478W WO2022066714A3 WO 2022066714 A3 WO2022066714 A3 WO 2022066714A3 US 2021051478 W US2021051478 W US 2021051478W WO 2022066714 A3 WO2022066714 A3 WO 2022066714A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart failure
sfrp
protect
delivery
mitral regurgitation
Prior art date
Application number
PCT/US2021/051478
Other languages
French (fr)
Other versions
WO2022066714A2 (en
Inventor
Zahra ALVANDI
Joyce Bischoff
Robert Levine
Original Assignee
Children's Medical Center Corporation
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation, The General Hospital Corporation filed Critical Children's Medical Center Corporation
Publication of WO2022066714A2 publication Critical patent/WO2022066714A2/en
Publication of WO2022066714A3 publication Critical patent/WO2022066714A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are methods of treating or reducing the risk of mitral regurgitation (MR) or heart failure, the method comprising administering to a subject in need thereof an effective amount of a secreted frizzled related protein 3 (sFRP3) polypeptide or a FOXM1 inhibitor.
PCT/US2021/051478 2020-09-22 2021-09-22 Delivery of sfrp-3 or foxm1 inhibitor to protect from and treat mitral regurgitation and heart failure WO2022066714A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063081847P 2020-09-22 2020-09-22
US63/081,847 2020-09-22

Publications (2)

Publication Number Publication Date
WO2022066714A2 WO2022066714A2 (en) 2022-03-31
WO2022066714A3 true WO2022066714A3 (en) 2022-04-28

Family

ID=80844752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/051478 WO2022066714A2 (en) 2020-09-22 2021-09-22 Delivery of sfrp-3 or foxm1 inhibitor to protect from and treat mitral regurgitation and heart failure

Country Status (1)

Country Link
WO (1) WO2022066714A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763926A (en) * 2023-07-03 2023-09-19 复旦大学附属中山医院 Application of FOXM1 inhibitor in preparation of heart failure resistant medicines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140193845A1 (en) * 2008-04-30 2014-07-10 The Governing Council Of The University Of Toronto Use of sfrp-3 in the assessment of heart failure
US9279012B2 (en) * 2005-08-19 2016-03-08 The Brigham And Women's Hospital, Inc. Method of reducing cell death by administering a nucleic acid encoding a paracrine factor of a mesenchymal stem cell

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9279012B2 (en) * 2005-08-19 2016-03-08 The Brigham And Women's Hospital, Inc. Method of reducing cell death by administering a nucleic acid encoding a paracrine factor of a mesenchymal stem cell
US20140193845A1 (en) * 2008-04-30 2014-07-10 The Governing Council Of The University Of Toronto Use of sfrp-3 in the assessment of heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASKEVOLD, E.T. ET AL.: "Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).", PLOS ONE, vol. 10, no. 8, 19 August 2015 (2015-08-19), pages 1 - 13, XP055925934, DOI: 10.1371/journal.pone.0133970 *

Also Published As

Publication number Publication date
WO2022066714A2 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
Ackermann et al. Neuronal pathways in tendon healing and tendinopathy: update
Angeletti et al. Healing rituals and sacred serpents
Hellstrom et al. Peyronie's disease: etiology, medical, and surgical therapy
CR20210489A (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
Groneberg et al. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors
Bonetto et al. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice
WO2022066714A3 (en) Delivery of sfrp-3 or foxm1 inhibitor to protect from and treat mitral regurgitation and heart failure
ATE151293T1 (en) IGF-I TO IMPROVE THE NEURAL SITUATION
McFarlane et al. Role of the natriuretic peptide system in cardiorenal protection
MX2022011804A (en) Use of agents for treatment of respiratory conditions.
DE69526937T2 (en) USE OF METHANBISPHOSPHONIC ACID DERIVATIVES FOR TREATING LOSSED PROSTHESES
MX2022004577A (en) Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors.
WO2007084544A3 (en) Methods of treating or preventing tissue damage caused by increased blood flow
Li et al. The potential roles of tendon stem/progenitor cells in tendon aging
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
WO2020102740A3 (en) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
Tonk et al. Platelet rich plasma versus laser therapy in lateral epicondylitis of elbow
WO2022076556A3 (en) Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
MX2021014315A (en) 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same.
NO975360D0 (en) Peptide which inhibits elevated blood triglyceride levels and agents containing said peptide as active component
JP5706163B2 (en) Treatment of fibrosis and liver disease
KR101824450B1 (en) Medicine Kit Reinforcing Fat Decompostion Function and Botox Function Comprising Hyaluronidase
JP6041812B2 (en) Methods for promoting healing of connective tissue damage and disorders
US11376280B2 (en) Treating rotator cuff conditions
Vasuki et al. Comparative study of papaya dressing versus normal saline dressing in healing of ulcers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21873323

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21873323

Country of ref document: EP

Kind code of ref document: A2